Prevalence and prognostic value of baseline sarcopenia in hematologic malignancies: a systematic review
Frontiers in Oncology · 14.12.2023 · 13
DOI: 10.3389/fonc.2023.1308544 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Oncology, online erschienen am 14.12.2023. Verfasst von Xiaofeng Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Center of Gerontology and Geriatrics, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The correlation between sarcopenia and hematological malignancy prognosis is still controversial.
Design
A systematic review and meta-analysis.
Objectives
To explore sarcopenia’s prevalence and prognostic value in hematologic malignancies. Data sources and methods We searched Embase, MEDLINE, and Cochrane Library through Ovid SP using an appropriate search strategy on August 28, 2022, and updated the search results on January 9, 2023. Study quality was assessed using the Newcastle-Ottawa scale. The pooled prevalence of sarcopenia was calculated with a 95% confidence interval (CI). Relationships between sarcopenia and prognostic value were expressed as hazard ratio (HR) and 95% CI. HR means the probability of something undesirable, i.e., death or disease progression.
Results
The search identified more than 3992 studies, and 21 (3354 patients, median or mean age ranging from 36 to 78 years) were finally included. The risk of bias in the studies was low to medium. All included studies were diagnosed based on low muscle mass (LMM). Muscle mass was assessed mainly through imaging technologies, and different cut-offs were applied to determine LMM. The prevalence of sarcopenia was 44.5%, which could fluctuate by age. Subgroup analysis showed that older people had a higher sarcopenic rate than the non-elderly group. Sarcopenia resulted in an inferior prognosis [overall survival: HR 1.821, 95% CI 1.415-2.343; progression-free survival: HR 1.703, 95% CI 1.128-2.571).
Conclusion
Sarcopenia has a prevalence of over 30% in malignant hematologic patients and is associated with a poorer prognosis. Future studies with a standardized sarcopenia diagnostic criterion were needed to investigate sarcopenia’s prevalence and prognostic effects in hematologic malignancies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Center of Gerontology and Geriatrics, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
- Sichuan University Library, Sichuan University, Chengdu, China.
Zitieren
APA
Zeng, X., Zhang, L., Zhang, Y., Jia, S., Lin, T., Zhao, X., & Huang, X. (2023). Prevalence and prognostic value of baseline sarcopenia in hematologic malignancies: a systematic review. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1308544
Vancouver
Zeng X, Zhang L, Zhang Y, Jia S, Lin T, Zhao X, et al. Prevalence and prognostic value of baseline sarcopenia in hematologic malignancies: a systematic review. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1308544
BibTeX
@article{Zeng2023,
author = {Zeng, Xiaofeng and Zhang, Liying and Zhang, Yu and Jia, Shuli and Lin, Taiping and Zhao, Xuman and Huang, Xiaoli},
title = {Prevalence and prognostic value of baseline sarcopenia in hematologic malignancies: a systematic review},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1308544}
}
EUVIMED